PF 5297909

Drug Profile

PF 5297909

Alternative Names: PF-05297909; PF-5297909

Latest Information Update: 16 May 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Class Antidementias; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 10 May 2012 Discontinued - Phase-I for Alzheimer's disease in USA (PO)
  • 29 Feb 2012 Pfizer completes a phase I trial in Healthy volunteers in USA (NCT01462851)
  • 27 Oct 2011 Phase-I clinical trials in Alzheimer's disease (healthy volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top